ArticleBMC medical research methodology2026
An interpretable XGboost algorithm for predicting 30-day mortality in acute pancreatitis using routine biomarkers.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo develop and validate a machine learning (ML) algorithm for predicting 30-day mortality in adult patients with acute pancreatitis (AP) using routinely readily available laboratory parameters.
methodsThis retrospective cohort study analyzed 965 consecutive AP patients hospitalized between January 2017 and December 2019. Feature selection was performed using Least Absolute Shrinkage and Selection Operator (LASSO) regression, followed by the evaluation of eleven machine learning algorithms. Model performance was assessed using via the area under the receiver operating characteristic curve (AUC). The optimal model was further interpreted using SHapley additive explanation (SHAP).
resultsThe overall 30-day mortality rate was 4.5% (43/965). Among the evaluated algorithms, extreme gradient boosting (XGboost) demonstrated the best performance in both the development and validation cohorts. SHAP analysis identified creatine kinase (CK) as the most influential predictor, followed by lactate dehydrogenase (LDH), age, prothrombin time (PT), and carbohydrate antigen 19 - 9 (CA19-9). A simplified algorithm incorporating only the top five features achieved near-perfect discrimination in the development cohort (AUC = 1.000) and maintained robust performance in the validation cohort (AUC = 0.847). This five-feature XGboost algorithm showed superior performance compared to conventional prognostic scores in the development cohort.
conclusionAn interpretable XGboost algorithm incorporating five key parameters (CK, LDH, age, PT, CA19-9) shows potential to predict predicts 30-day mortality in AP patients. This single-center retrospective model demonstrates promising internal performance but requires prospective multicenter external validation before clinical implementation. The web-based platform is provided as a research prototype for proof-of-concept and must not be used for real-time clinical decision-making at this stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.